Amarin (AMRN) news
Recent news
U.S. Supreme Court rules in favor of generic drugmaker Hikma in 'skinny label' patent dispute over Amarin heart drug Vascepa
In a landmark ruling on June 4, 2026, the U.S. Supreme Court sided with generic drugmaker Hikma Pharmaceuticals USA Inc. in a patent dispute involving Amarin Pharma, Inc. over the use of a "skinny label" for a generic version of Amarin’s heart drug Vascepa. The decision clarifies legal boundaries…
AInvest Wire · Jun 4, 2026Amarin Corp Q2 2024 Adj. EPS $0.01 Beats $(0.04) Estimate, Sales $67.500M Beat $51.019M Estimate
Amarin Corp Q2 2024 Adj. EPS $0.01 Beats $(0.04) Estimate, Sales $67.500M Beat $51.019M Estimate Introduction: Amarin Corporation plc (NASDAQ: AMRN) recently reported its Q2 2024 financial results, showcasing better-than-expected adjusted earnings per share (EPS) and sales. This article delves into…
AInvest Wire · Jul 31, 2024HLS Therapeutics Has Entered Into A Product Listing Agreement With The Province Of Alberta, For The Listing And Public Reimbursement Of Amarin's Vascepa (Icosapent Ethyl), Effective August 1, 2024
AInvest Wire · Jul 29, 2024Amarin falls on CEO exit and Vascepa coverage update
Amarin falls on CEO exit and Vascepa coverage update In a significant development for Amarin Corporation plc (NASDAQ: AMRN), the European Patent Office (EPO) recently granted the company a new patent covering VAZKEPA (icosapent ethyl), extending its exclusivity by eight years into 2039 [1]. This…
AInvest Wire · Jun 4, 2024Amarin Corp Q3 Adjusted EPS $(0.00) Beats $(0.04) Estimate, Sales $66.06M Beat $58.65M Estimate
AInvest Wire · Nov 1, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.